MedCompanion

Diabetic Foot Infection

SSTI

Source: IDMP View on spectrum chart →
Patient + scenario modifiers
Patient
Clinical scenario / source

Annotations only — chart still shows the full chemistry of each drug.

1. Clinical Syndrome

Infection of soft tissue and/or bone of the foot in a person with diabetes, occurring below the malleoli. Diagnosed clinically by IDSA / IWGDF criteria: ≥2 signs of inflammation (erythema, warmth, induration, tenderness, pain, purulent discharge) plus a wound.

Severity grading (IDSA / IWGDF):

  • Mild — local infection, ≤2 cm erythema, no systemic signs.
  • Moderate — local infection, >2 cm erythema OR deeper structures (abscess, fasciitis, septic arthritis, osteomyelitis), no systemic signs.
  • Severe — local infection with systemic signs (SIRS / sepsis).

Osteomyelitis present when: probe-to-bone positive, exposed bone, ulcer >2 weeks despite offloading, ESR >70, imaging confirms.

Excludes: non-infected diabetic foot ulcer (no inflammatory signs — wound care + offloading only, no antibiotics), Charcot foot without infection, pure vascular ulcer.

2. Pathogens

Consider the patient: Severity (mild → narrow oral; severe → broad IV), prior antibiotic exposure (MDRO risk), prior MRSA / Pseudomonas isolate, ischemia (perfusion drives healing), bone involvement on probe / imaging / biopsy.

Consider the case: Mild + chronic → S. aureus + strep dominate, polymicrobial less common. Moderate-severe + chronic / prior abx → polymicrobial including anaerobes + GNR. Severe sepsis with foot source → cover MRSA + Pseudomonas + anaerobes empirically. Wound-bed soaked / macerated → think Pseudomonas. Foul-smelling, gangrenous, deep abscess → think anaerobes.

Common

Less common

3. Empiric Therapy

TierFirst choiceAlternativesDurationComments
Outpatient
  • 1–2 DS tablets · PO BID · PO · 7–14 days
  • 875 mg · PO BID · PO · 7–14 days

    Add or substitute when strep coverage desired or as monotherapy for MSSA + strep + anaerobes.

  • 500 mg · PO QID · PO

    MSSA + strep only — no anaerobe coverage; pair with metronidazole or use amox-clav if anaerobes a concern.

  • 450 mg · PO TID · PO

    Covers MSSA, strep, anaerobes. Watch for clinda-resistant MRSA.

  • 100 mg · PO BID · PO

    MRSA-active oral option; pair with amox-clav for full coverage.

1–2 weeks for mild soft-tissue DFI; longer if osteomyelitis confirmed**Mild DFI, no prior MRSA, no anaerobe concerns.** Outpatient management feasible with reliable follow-up + offloading + wound care + vascular assessment.
Admitted to ward
  • 3 g · q6h · IV · 7–14 days
  • 2 g · q24h · IV · 7–14 days

    Plus metronidazole 500 mg q8h for anaerobe coverage.

  • 1 g · q24h · IV

    OPAT-friendly; covers anaerobes + GNR + MSSA; no Pseudomonas coverage.

7–14 days (soft tissue); 4–6 weeks (osteomyelitis with retained bone); 2 weeks if amputation removes all infected bone**Moderate DFI, no prior MRSA, no Pseudomonas risk.** Covers MSSA, strep, enterococcus, GNR, anaerobes. Add vancomycin for MRSA risk.
ICU — Pseudomonas risk
  • load + AUC-guided · — · IV
  • 4.5 g · q6h (extended infusion) · IV · 7–14 days soft tissue; 4–6 weeks bone
  • 1 g · q8h · IV

    ESBL risk or pip-tazo-resistant prior isolate.

7–14 days (soft tissue); 4–6 weeks (osteomyelitis)**Severe DFI / sepsis / prior MDRO / chronic ischemia.** Surgical evaluation urgent — debridement / amputation decisions co-managed with vascular + ortho.

Add coverage if:

MRSA coverage
  • Prior MRSA isolate
  • Recent healthcare exposure
  • Local prevalence >50%
  • Severe disease

Add:

  • load + AUC-guided · — · IV
Pseudomonas coverage
  • Chronic macerated / soaked wound
  • Prior Pseudomonas isolate
  • Recent broad-spectrum abx
  • Severe / chronic non-healing

Add:

  • 4.5 g · q6h · IV

    Or cefepime / meropenem.

ESBL coverage
  • Prior ESBL isolate
  • Broad-spectrum abx exposure within 90 days
  • Severe disease

Add:

  • 1 g · q8h · IV

4. Directed Therapy

Source control + offloading + vascular assessment are non-negotiable. Antibiotics alone fail in DFI with retained necrotic tissue, untreated ischemia, or continued weight-bearing.

Duration tied to depth + source control:

  • Mild soft-tissue → 1–2 weeks.
  • Moderate soft-tissue → 1–3 weeks.
  • Osteomyelitis with retained infected bone → 4–6 weeks.
  • Osteomyelitis after amputation removing all infected bone → 2–5 days (just soft-tissue duration).
  • Persistent dead bone fragments after debridement → 3 months of suppression while bone consolidates.

Narrow to culture data — use deep tissue / bone cultures, not superficial swabs (low yield, high contamination). Probe-to-bone positive + plain film changes → empiric bone-relevant agent.

Vascular + ortho consultation early — perfusion drives healing; revascularization may be needed before / during antibiotic therapy. Amputation level decisions are multidisciplinary.

Adjuncts: tight glycemic control (improves immune function + wound healing), offloading (total contact cast, removable boot), wound care (debridement, dressings), nutritional optimization.

5. Monitoring

Resolution: erythema, warmth, drainage, granulation. Imaging (X-ray q2–4 weeks for osteo) — bone changes lag clinical improvement by weeks.

Healing markers: ESR + CRP trending down, wound size reduction. Persistent draining sinus → suspect retained bone fragment, deep abscess, or inadequate vascular supply.

Toxicity: vanc AUC + Cr; pip-tazo + vanc AKI; FQ tendinopathy / QT / dysglycemia (esp problematic in diabetes); TMP-SMX hyperK + Cr bump.

Pearls

Send deep tissue / bone cultures, not surface swabs — surface flora is meaningless. Probe-to-bone is highly sensitive + specific for osteomyelitis in DFI — when positive, treat as osteo. Plain films are insensitive early (changes lag 2 weeks); MRI is the imaging of choice when osteo suspected but plain film equivocal. Amputation often removes all infected bone — antibiotic duration then drops to 2 weeks (treat as soft-tissue). No anaerobe coverage needed for mild infections — only for moderate-severe, deep, ischemic, or chronic. Vascular consult is mandatory in every diabetic foot ulcer with infection — perfusion drives healing. TMP-SMX + amox-clav is a great oral combo for moderate non-severe DFI when MRSA risk + anaerobe coverage both desired.

References